[go: up one dir, main page]

GT200600261A - Formulaciones de diclofenac y metodos para usarlas - Google Patents

Formulaciones de diclofenac y metodos para usarlas

Info

Publication number
GT200600261A
GT200600261A GT200600261A GT200600261A GT200600261A GT 200600261 A GT200600261 A GT 200600261A GT 200600261 A GT200600261 A GT 200600261A GT 200600261 A GT200600261 A GT 200600261A GT 200600261 A GT200600261 A GT 200600261A
Authority
GT
Guatemala
Prior art keywords
diclofenac
methods
hygroscopic
powder
formulations
Prior art date
Application number
GT200600261A
Other languages
English (en)
Inventor
Giorgio Reiner
Alberto Reiner
Andreas Meyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600261(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600261A publication Critical patent/GT200600261A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A SACHÉS DE DICLOFENAC EN POLVO SELLADOS HERMÉTICAMENTE Y MÉTODOS PARA HACERLOS QUE COMPRENDE MEZCLAR DICLOFENAC EN POLVO CON UN TAMAÑO DE PARTÍCULA FINO DE UN DILUYENTE NO HIGROSCÓPICO TAL COMO MANITOL PARA FORMAR UNA PRIMERA PREMEZCLA, MEZCLAR LA PREMERA PREMEZCLA CON UNA SEGUNDA MEZCLA QUE COMPRENDE UN TAMAÑO GRUESO DE PARTÍCULA DEL DILUYENTE NO HIGROSCÓPICO E INGREDIENTES ADICIONALES OPCIONALES Y RELLENAR LOS RECIPIENTES SACHÉS CON DOSIS UNITARIAS DE LA MEZCLA RESULTANTE.
GT200600261A 2005-06-17 2006-06-16 Formulaciones de diclofenac y metodos para usarlas GT200600261A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69202405P 2005-06-17 2005-06-17
US69175705P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
GT200600261A true GT200600261A (es) 2007-02-05

Family

ID=37396065

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600261A GT200600261A (es) 2005-06-17 2006-06-16 Formulaciones de diclofenac y metodos para usarlas

Country Status (24)

Country Link
US (7) US7759394B2 (es)
EP (4) EP2402003B1 (es)
KR (1) KR101352130B1 (es)
CN (3) CN101272768A (es)
AR (1) AR057378A1 (es)
AU (1) AU2006257072B2 (es)
BR (1) BRPI0612245A2 (es)
CA (2) CA2632375C (es)
EC (1) ECSP077989A (es)
ES (3) ES2717879T3 (es)
GT (1) GT200600261A (es)
HK (1) HK1213814A1 (es)
JO (1) JO3352B1 (es)
MX (1) MX2007016072A (es)
NO (1) NO342336B1 (es)
NZ (1) NZ564002A (es)
PE (1) PE20070074A1 (es)
PL (1) PL1890680T3 (es)
PT (1) PT1890680T (es)
RU (1) RU2432160C2 (es)
TR (1) TR201706038T4 (es)
TW (1) TW200740470A (es)
WO (1) WO2006133954A2 (es)
ZA (1) ZA200710858B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974595B1 (en) * 1996-05-17 2005-12-13 Proethic Pharmaceuticals, Inc. Pharmaceutical compositions based on Diclofenae
JO3352B1 (ar) * 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
US7700125B2 (en) * 2006-02-07 2010-04-20 Kowa Pharmaceuticals America, Inc. Moisture resistant container systems for rapidly bioavailable dosage forms
EP2471522A1 (en) * 2007-05-24 2012-07-04 Novartis AG Oral dosage form providing fast absorption of drug
UA106231C2 (uk) 2009-04-24 2014-08-11 Айсьютика Пти Лтд Разова доза фармацевтичної композиції індометацину (варіанти)
MX337619B (es) * 2009-04-24 2016-03-10 Iceutica Pty Ltd Una formulacion novedosa de diclofenaco.
WO2011036114A1 (en) * 2009-09-25 2011-03-31 Novartis Ag Oral pharmaceutical composition comprising diclofenac
FR2984165B1 (fr) * 2011-12-16 2014-06-27 Pharmeuro Traitement des crises de migraines, notamment d'algies vasculaires de la face
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US9855234B2 (en) 2014-07-08 2018-01-02 Insys Development Company, Inc. Diclofenac sublingual spray
CN106580886A (zh) * 2016-12-05 2017-04-26 北京万全德众医药生物技术有限公司 一种双氯芬酸钾散剂及其制备方法
WO2019030773A1 (en) * 2017-08-10 2019-02-14 Sarudbhava Formulations Private Limited DICLOFENAC COMPOSITIONS WITH LOW DOSE
EP3893865A1 (en) 2018-12-14 2021-10-20 Apr Applied Pharma Research S.A. Ready to use diclofenac stick packs
CA3180560A1 (en) * 2020-06-10 2021-12-16 Alberto Reiner Bioavailable sugar-based diclofenac formulations
EP3928766A1 (en) 2020-06-26 2021-12-29 Usso Barnas Pharmaceutical composition and use thereof
US20220241230A1 (en) * 2021-02-03 2022-08-04 Patrin Pharma, Inc. Diclofenac sachet composition
CN115317464B (zh) * 2022-09-01 2023-08-08 苏州弘森药业股份有限公司 一种双氯芬酸钾微胶囊及其制备方法
GB2634218A (en) * 2023-09-29 2025-04-09 Approved Pharma Solutions Ltd Powder for oral solution formulations
GB202401873D0 (en) * 2024-02-12 2024-03-27 Hawkins John Lipophilic drug suspensions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558690A (en) * 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
US4344929A (en) 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS57191962A (en) 1981-05-20 1982-11-25 Hitachi Ltd Fuel cell
IT1209667B (it) * 1985-11-12 1989-08-30 Zambon Spa Composizione effeverscente adattivita' analgesica.
CH673395A5 (es) * 1987-01-30 1990-03-15 Ciba Geigy Ag
US5211957A (en) 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
IT1226549B (it) 1988-07-12 1991-01-24 Resa Farma Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
GB8824392D0 (en) 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
GB8920693D0 (en) 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions
DE59105562D1 (de) 1990-06-28 1995-06-29 Ciba Geigy Ag Alpha-Carbonylphenylacetonitrilderivate als Stabilisatoren für organische Materialien.
EP0466650A2 (en) 1990-07-11 1992-01-15 Warner-Lambert Company Improvements in non-steroidal anti-inflammatory therapy
MX9300110A (es) 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
CA2141582C (en) 1992-08-05 2003-09-30 Angelo Mario Morella Pelletised pharmaceutical composition
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
DE59410143D1 (de) 1993-09-07 2002-08-01 Gergely Gerhard Modifizierte Kristalle einer festen, essbaren, organischen Säure
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
JPH10500982A (ja) 1994-05-27 1998-01-27 ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ 医薬組成物
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
IT1283029B1 (it) * 1996-05-17 1998-04-03 Resa Farma Composizioni farmaceutiche a base di diclofenac
DE19538555A1 (de) 1995-10-17 1997-04-24 Beiersdorf Ag Gegen Akne und entzündete Comedonen wirksame Wirkstoffkombinationen
ATE260646T1 (de) * 1996-04-16 2004-03-15 Novartis Consumer Health Sa Schnell zerfallende orale dosierungsform
US6974595B1 (en) * 1996-05-17 2005-12-13 Proethic Pharmaceuticals, Inc. Pharmaceutical compositions based on Diclofenae
US20060013896A1 (en) * 1996-05-17 2006-01-19 Giorgio Reiner Methods of treating acute pain using diclofenac
US7687542B2 (en) * 1996-05-17 2010-03-30 Kowa Pharmaeuticals America, Inc. Rapidly bioavailable tablet and capsule formulations of diclofenac
US5854279A (en) 1996-06-04 1998-12-29 Eisai Co., Ltd Therapeutic agent for dermatosis
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
JP5026635B2 (ja) 1998-09-10 2012-09-12 ニュコメデ ダンマルク アンパーツセルスカブ 医薬物質の迅速放出医薬組成物
ES2199916T3 (es) * 2001-11-20 2004-03-01 Apr Applied Pharma Research S.A. Composiciones farmaceuticas hidrosolubles no efervescentes que comprenden farmacos antiinflamatorios no esteroideos.
RU2202359C1 (ru) * 2002-05-18 2003-04-20 Агафонов Сергей Александрович Лечебно-профилактическое средство
GB2401547B (en) * 2003-05-08 2005-07-20 Nektar Therapeutics Uk Ltd Particulate materials
JO3352B1 (ar) * 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
US7700125B2 (en) * 2006-02-07 2010-04-20 Kowa Pharmaceuticals America, Inc. Moisture resistant container systems for rapidly bioavailable dosage forms
US7939561B2 (en) * 2006-02-07 2011-05-10 Apr Applied Pharma Research S.A. Blister packaging for acute pain regimens

Also Published As

Publication number Publication date
AU2006257072B2 (en) 2012-08-16
KR20080024202A (ko) 2008-03-17
PT1890680T (pt) 2017-05-05
US20090197961A1 (en) 2009-08-06
US8097651B2 (en) 2012-01-17
RU2432160C2 (ru) 2011-10-27
US9827197B2 (en) 2017-11-28
RU2008101784A (ru) 2009-07-27
US20170319484A1 (en) 2017-11-09
US8927604B2 (en) 2015-01-06
EP1890680A2 (en) 2008-02-27
TW200740470A (en) 2007-11-01
PL1890680T3 (pl) 2017-08-31
ES2912897T3 (es) 2022-05-30
CN104856959A (zh) 2015-08-26
AR057378A1 (es) 2007-11-28
ES2717879T3 (es) 2019-06-26
CA2632375A1 (en) 2006-12-21
NO342336B1 (no) 2018-05-07
JO3352B1 (ar) 2019-03-13
MX2007016072A (es) 2008-03-10
CN112755014A (zh) 2021-05-07
NO20080352L (no) 2008-03-17
US20200323776A1 (en) 2020-10-15
HK1213814A1 (zh) 2016-07-15
EP3103441B1 (en) 2022-03-16
EP2705837A1 (en) 2014-03-12
CA2932603A1 (en) 2006-12-21
US20150064258A1 (en) 2015-03-05
US7759394B2 (en) 2010-07-20
ZA200710858B (en) 2008-12-31
EP2402003A2 (en) 2012-01-04
EP3103441A1 (en) 2016-12-14
CN101272768A (zh) 2008-09-24
EP2402003B1 (en) 2020-05-06
PE20070074A1 (es) 2007-02-08
CA2632375C (en) 2016-08-16
EP2705837B1 (en) 2019-02-20
EP1890680B1 (en) 2017-03-08
WO2006133954A2 (en) 2006-12-21
US20070015831A1 (en) 2007-01-18
KR101352130B1 (ko) 2014-02-06
ECSP077989A (es) 2008-03-26
EP2402003A3 (en) 2012-05-09
BRPI0612245A2 (pt) 2010-10-26
NZ564002A (en) 2011-03-31
CA2932603C (en) 2017-08-08
AU2006257072A1 (en) 2006-12-21
WO2006133954A3 (en) 2007-07-26
ES2641889T3 (es) 2017-11-14
TR201706038T4 (tr) 2019-02-21
US20130245122A1 (en) 2013-09-19
US20100204330A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
GT200600261A (es) Formulaciones de diclofenac y metodos para usarlas
AR057180A1 (es) Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion
ECSP15007335A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR11418A (es) Trans-clomifeno para el sindrome metabolico
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
MY196173A (en) Cot Modulators And Methods Of Use Thereof
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
NZ709958A (en) Enhanced stability of novel liquid compositions
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
CL2019000246A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CL2015002667A1 (es) Dispensador
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
MX2016012363A (es) Espuma quimica que se remueve con enjuague que contiene peroxido de benzoilo.
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
CL2013001250A1 (es) Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion.
BR112016006171A2 (pt) formulações de espuma e dispositivo para sua entrega
PH12022551468A1 (en) Compounds active towards nuclear receptors
WO2013104892A8 (en) Application of high dose compounds via inhalation
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
EA201490615A1 (ru) Состав (rs)-2-(2-оксо-4-фенилпирролидин-1-ил)ацетамид, обладающий модуляторной активностью с соразмерным влиянием, фармацевтический состав субстанции (варианты) и его применение, композиция (варианты)
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
CL2012001507A1 (es) Un kit de formula infantil que posee un envase común dividido por al menos un elemento divisorio, múltiples dosis de una formula infantil en forma de polvo, múltiples dosis de al menos un tipo de prebióticos liberados en cantidades incrementales discretas visibles al ojo humano.
BR112015027247A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas
HK1221412A1 (zh) 囊泡